David DiLillo
Senior Director, Immuno-Oncology Regeneron Pharmaceuticals
Seminars
Tuesday 19th May 2026
Next-Generation HLA/Peptide-Targeted Therapies: Lessons Learned from Comparing TCR-T Versus TCR Mimetic CAR-T
2:00 pm
- State-of-the-art techniques for discovering tumor-specific HLA/peptide targets and technologies for generating TCRs and TCR mimetic antibodies
- Directly compare and contrast TCR-T versus TCR mimetic CAR-T cells in vitro and in vivo
- Engineering T-cells and combinations with biologics for optimal deployment of HLA/ peptide-targeted therapies in the clinic
